Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan, MD Prados, T Tihan… - Journal of the …, 2005 - academic.oup.com
Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01 …
AB Lassman, MR Rossi, JR Razier, LE Abrey… - Clinical Cancer …, 2005 - AACR
Purpose: We investigated the molecular effect of the epidermal growth factor receptor
(EGFR) inhibitors erlotinib and gefitinib in vivo on all available tumors from patients treated …
(EGFR) inhibitors erlotinib and gefitinib in vivo on all available tumors from patients treated …
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Background The epidermal growth factor receptor (EGFR) is frequently amplified,
overexpressed, or mutated in glioblastomas, but only 10 to 20 percent of patients have a …
overexpressed, or mutated in glioblastomas, but only 10 to 20 percent of patients have a …
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
JN Sarkaria, L Yang, PT Grogan, GJ Kitange… - Molecular cancer …, 2007 - AACR
In the current study, we examined a panel of serially passaged glioblastoma xenografts, in
the context of an intracranial tumor therapy response model, to identify associations …
the context of an intracranial tumor therapy response model, to identify associations …
The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications
JL Nakamura - Expert opinion on therapeutic targets, 2007 - Taylor & Francis
Activated epidermal growth factor receptor (EGFR) has emerged as an important therapeutic
target for a variety of solid tumors, particularly malignant gliomas. Mutation or amplification of …
target for a variety of solid tumors, particularly malignant gliomas. Mutation or amplification of …
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ
A Schulte, K Liffers, A Kathagen, S Riethdorf… - Neuro …, 2013 - academic.oup.com
Background The treatment efficacy of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors like erlotinib has not met expectations for glioblastoma therapy, even for …
kinase inhibitors like erlotinib has not met expectations for glioblastoma therapy, even for …
Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments
Despite advances in diagnosis and treatment made over the past two decades, high-grade
gliomas are still incurable neoplasms. Moreover, after failing adjuvant therapy, few active …
gliomas are still incurable neoplasms. Moreover, after failing adjuvant therapy, few active …
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme
CA Learn, TL Hartzell, CJ Wikstrand, GE Archer… - Clinical cancer …, 2004 - AACR
Purpose: We have reported previously that tumors expressing wild-type epidermal growth
factor receptor (EGFR) in a murine model are sensitive to the EGFR tyrosine kinase inhibitor …
factor receptor (EGFR) in a murine model are sensitive to the EGFR tyrosine kinase inhibitor …
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
WKA Yung, JJ Vredenburgh, TF Cloughesy… - Neuro …, 2010 - academic.oup.com
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is active in
glioblastoma. We evaluated erlotinib efficacy in patients with first-relapse glioblastoma and …
glioblastoma. We evaluated erlotinib efficacy in patients with first-relapse glioblastoma and …
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma
JS Guillamo, S de Boüard, S Valable, L Marteau… - Clinical cancer …, 2009 - AACR
Purpose: Epidermal growth factor receptor (EGFR) signal transduction pathways are
implicated in malignant glioma aggressiveness and promote tumor cell invasion …
implicated in malignant glioma aggressiveness and promote tumor cell invasion …